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A bs tr ac t
Background
Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in 
men. We examined microRNA expression patterns, survival, and response to inter-
feron alfa in both men and women with the disease.
Methods
We analyzed three independent cohorts that included a total of 455 patients with 
hepatocellular carcinoma who had undergone radical tumor resection between 
1999 and 2003. MicroRNA-expression profiling was performed in a cohort of 241 
patients with hepatocellular carcinoma to identify tumor-related microRNAs and 
determine their association with survival in men and women. In addition, to validate 
our findings, we used quantitative reverse-transcriptase–polymerase-chain-reaction 
assays to measure microRNAs and assess their association with survival and re-
sponse to therapy with interferon alfa in 214 patients from two independent, pro-
spective, randomized, controlled trials of adjuvant interferon therapy.
Results
In patients with hepatocellular carcinoma, the expression of miR-26a and miR-26b 
in nontumor liver tissue was higher in women than in men. Tumors had reduced 
levels of miR-26 expression, as compared with paired noncancerous tissues, which 
indicated that the level of miR-26 expression was also associated with hepatocellular 
carcinoma. Moreover, tumors with reduced miR-26 expression had a distinct tran-
scriptomic pattern, and analyses of gene networks revealed that activation of sig-
naling pathways between nuclear factor κB and interleukin-6 might play a role in 
tumor development. Patients whose tumors had low miR-26 expression had shorter 
overall survival but a better response to interferon therapy than did patients whose 
tumors had high expression of the microRNA.
Conclusions
The expression patterns of microRNAs in liver tissue differ between men and women 
with hepatocellular carcinoma. The miR-26 expression status of such patients is 
associated with survival and response to adjuvant therapy with interferon alfa.
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Hepatocellular carcinoma is com-mon globally, with dismal outcomes and an increasing incidence in the United 
States.1 To date, surgery remains the most effec-
tive treatment with curative potential. However, 
only about 10 to 20% of patients with hepatocel-
lular carcinoma are currently eligible for surgical 
intervention. In addition, patients who undergo 
curative resection often have a high rate of re-
lapse. Therapies such as transcatheter arterial 
chemoembolization (TACE) and interferon alfa 
may prolong survival in some patients. However, 
the response is often not satisfactory because of 
the limited ability to identify patients who are 
most likely to benefit from such targeted adjuvant 
therapies.2-5 The recent findings of the Sorafenib 
Hepatocellular Carcinoma Assessment Random-
ized Protocol (SHARP) trial (ClinicalTrials.gov 
number, NCT00105443)6 were encouraging with 
respect to the use of sorafenib as a therapeutic 
agent. However, the survival benefit was modest. 
There is a need for molecular tools that can be 
used to stratify patients with respect to progno-
sis and response to therapy.
One of the key features of hepatocellular car-
cinoma is the higher incidence in men than in 
women, by a factor of two to six among various 
ethnic groups.7 Classic in vivo carcinogenesis ex-
periments also reveal a higher susceptibility to 
hepatocellular carcinoma in male rodents.8-11 
Moreover, women with this disease tend to have 
longer survival than men.12-14 These findings 
suggest that the biologic features of the tumor 
and the host microenvironment may differ sig-
nificantly between the sexes and that sex-related 
factors may be associated with the prognosis. 
However, the underlying reasons for the lower 
incidence of hepatocellular carcinoma in women 
remain unclear. In a recent study, investigators 
found that one contributing factor may be that 
estrogen inhibits the induction of interleukin-6 
produced by Kupffer cells.11 The serum level of 
interleukin-6 is elevated in several cancers, includ-
ing hepatocellular carcinoma.15,16
MicroRNAs, small noncoding RNAs that regu-
late the translation of many genes, are excellent 
biomarkers for cancer diagnosis and prognosis.17-21 
Given the therapeutic and prognostic potential 
of microRNAs as biomarkers in hepatocellular 
carcinoma, we evaluated microRNA profiles of 
specimens of hepatocellular carcinomas and 
paired specimens of noncancerous tissue to 
search for microRNAs that are associated with 
sex and with hepatocellular carcinoma.
Me thods
Study Oversight
The study was approved by the institutional re-
view board at each study center. All patients from 
whom tissue samples were obtained provided 
written informed consent.
Clinical Specimens
We obtained snap-frozen or paraffin-embedded 
specimens of tumors and surrounding nontumor 
hepatic tissues from 455 patients with hepatocel-
lular carcinoma who had undergone radical re-
section between 1999 and 2003 at the Liver Can-
cer Institute of Fudan University in Shanghai 
(376 patients) or at the University of Hong Kong 
Medical Centre in Hong Kong (79 patients).4 Sam-
ples of normal liver tissue were obtained from 
eight disease-free liver donors.22
Our analyses involved three separate cohorts 
of patients. Cohort 1 consisted of 241 patients 
with hepatocellular carcinoma (test cohort) for 
whom microRNA microarray data were available, 
as described previously.21 Data from these pa-
tients were analyzed to search for microRNAs 
that were associated with sex and survival. We 
were able to analyze miR-26 expression in 224 
patients and survival in 217 patients. Cohorts 2 
and 3 consisted of 214 patients from prospective, 
randomized, controlled trials of adjuvant therapy 
with interferon alfa in patients with hepatocellu-
lar carcinoma.3,4 In cohort 2, data from 135 
patients were evaluated in an independent vali-
dation analysis to measure microRNA expres-
sion with the use of quantitative reverse-tran-
scriptase–polymerase-chain-reaction (qRT-PCR) 
assay. We were able to evaluate both miR-26 ex-
pression and survival in 118 patients. In cohort 
3, data from 79 patients (40 in the control group 
and 39 in the group that received interferon alfa) 
were evaluated to validate the association be-
tween miR-26 expression and the response to 
interferon alfa therapy.
Additional methods (including statistical analy-
sis) are described in detail in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org.
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R esult s
Characteristics of the Patients
Most of the patients in the three cohorts were 
men (85.1%), were long-term carriers of hepatitis 
B virus (HBV) (90.5%), and had cirrhosis (88.0%) 
and an elevated serum level of alpha-fetoprotein 
(62.2%); 84.4% of the patients had a single tumor 
nodule at the time of resection (Table 1, and Ta-
ble 1 in the Supplementary Appendix). Clinical 
variables were similar between the test and vali-
dation cohorts, with the exception of the serum 
alanine aminotransferase (ALT) level, tumor–
node–metastasis (TNM) stage, and status with 
respect to adjuvant therapy. Liver-inflammation 
activity in the patients with HBV-related hepato-
cellular carcinoma, as indicated by ALT levels, 
was significantly lower in patients in cohort 2 
than in those in either cohort 1 or cohort 3, and 
more patients in cohort 2 had early-stage tumors. 
In addition, 39 patients in cohort 1 had received 
prophylactic adjuvant therapies, but the differ-
ence in response did not appear to be significant 
(P = 0.90 by the log-rank test). In contrast, 53.3% 
of patients in cohort 2 and 49.4% in cohort 3 
had received “intention-to-cure” adjuvant thera-
py with interferon alfa, which improved overall 
survival.3,4
Association of MicroRNAs with Sex  
and Clinical Outcome
To search for differences in the expression of 
microRNAs between liver samples from men and 
those from women, we globally analyzed the 
microRNA expression profiles of 241 patients in 
cohort 1, in which both tumor and nontumor 
microRNA microarray data were available (Gene 
Expression Omnibus [GEO] accession number, 
GSE6857).21 To avoid potential confounding fac-
tors, an age-matched and balanced case set was 
used to identify microRNAs with different ex-
pression levels in men and women, consisting of 
all 30 women and two age-matched control groups 
of men, each consisting of 31 patients (groups G1 
and G2). The clinical characteristics of the women 
and the men in the two control groups were sim-
ilar (Table 2 in the Supplementary Appendix).
Class-comparison analysis of nontumor liver 
tissues revealed that 15 microRNAs were differ-
entially expressed in the comparison between the 
30 women and the first control group of men 
(G1), whereas 45 microRNAs differed in the com-
parison between the women and the second con-
trol group of men (G2). Seven microRNAs showed 
differential expression between women and men 
in both comparisons. In contrast, we identified 
only one microRNA, miR-129-2, that had differ-
ential expression in tumor tissue from women 
and from men in both comparisons (Table 3 in 
the Supplementary Appendix). Thus, there were 
more consistent differences in microRNA expres-
sion in nontumor hepatic tissue than in tumors.
In humans, there are three miR-26 members: 
miR-26a-1, miR-26a-2, and miR-26b; miR-26a-1 
was chosen for further analysis, since the differ-
ence in its level between sexes was most signifi-
cant, and it was most abundant. Analyses of 
data from 224 patients in cohort 1 showed that 
miR-26a-1 expression in normal hepatic tissue 
was significantly higher in women than in men 
(Fig. 1A). This finding was validated by the de-
termination of mature miR-26 expression in 26 
women and in 56 age-matched men with the use 
of qRT-PCR (Fig. 1B).
We then reasoned that miR-26 may act as a 
tumor-suppressor gene, and if so, the silencing 
of miR-26 would be a frequent event in tumors. 
Analyses showed that a significant reduction in 
miR-26a-1 expression in tumors, as compared 
with that in nontumor samples, was observed in 
patients with low levels of miR-26 expression 
(P<0.001) but not in those with high levels of 
miR-26 expression (P = 0.23) (Fig. 1C). The me-
dian factor change in the expression in tumors, 
as compared with nontumors, was 0.37 in pa-
tients with low miR-26a-1 expression and 0.98 in 
patients with high miR-26a-1 expression, which 
suggested that the silencing of miR-26 expres-
sion was associated only with low miR-26 expres-
sion. Moreover, low miR-26 expression, as com-
pared with high expression, was associated with 
reduced survival (Fig. 1D). The expression pat-
terns of all three miR-26 members and their as-
sociations with survival were similar (Fig. 1 in 
the Supplementary Appendix).
Tumors with Low miR-26 Expression
To test the hypothesis that tumors with low miR-
26 expression may be biologically distinct, we 
analyzed the 224 matched patients in cohort 1 
with available microRNA and messenger RNA 
(mRNA) microarray data. The mRNA microarray 
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Table 1. Clinical Characteristics of the Patients.*
Variable Cohort 1 (N = 241) Cohort 2 (N = 135) P Value†
Sex — no. (%) 0.87
Female 30 (12.4) 14 (10.4)
Male 211 (87.6) 111 (82.2)
Missing data 0 10 (7.4)
Age — yr 0.29
Median 50 50 
Range 13–83 20–77
Alanine aminotransferase — no. (%) <0.001
Normal, ≤50 U/liter 145 (60.2) 107 (79.3)
Elevated, >50 U/liter 96 (39.8) 16 (11.9)
Missing data 0 12 (8.9)
Hepatitis B virus — no. (%) 0.64
Negative 16 (6.6) 6 (4.4)
Positive 224 (92.9) 118 (87.4)
Missing data 1 (0.4) 11 (8.1)
Tumor size — no. (%) 0.91
≤3 cm 88 (36.5) 46 (34.1)
>3 cm 153 (63.5) 78 (57.8)
Missing data 0 11 (8.1)
Multinodular tumor — no. (%) 0.50
No 214 (88.8) 107 (79.3)
Yes 27 (11.2) 17 (12.6)
Missing data 0 11 (8.1)
Cirrhosis — no. (%) 0.08
No 17 (7.1) 16 (11.9)
Yes 223 (92.5) 108 (80.0)
Missing data 1 (0.4) 11 (8.1)
TNM stage — no. (%) <0.001
I 97 (40.2) 81 (60.0)
II 90 (37.3) 29 (21.5)
III or IV 54 (22.4) 14 (10.4)
Missing data 0 11 (8.1)
Alpha-fetoprotein — no. (%) 0.20
Negative, ≤20 ng/ml 77 (32.0) 49 (36.3)
Positive, >20 ng/ml 162 (67.2) 75 (55.6)
Missing data 2 (0.8) 11 (8.1)
Adjuvant therapy — no. (%)‡ <0.001
Yes 39 (16.2) 72 (53.3)
No 202 (83.8) 63 (46.7)
Survival (mo) 0.89
Median >60 67 
Range 2–67 2–82
* The clinical characteristics of the 79 patients in the validation cohort for interferon alfa therapy (cohort 3) are listed in 
Table 1 in the Supplementary Appendix. TNM denotes tumor–node–metastasis.
† A P value of less than 0.05 was considered to indicate statistical significance. P values were calculated with the use of 
Fisher’s exact test, except for age, which was calculated with the unpaired t-test; TNM, which was calculated with the 
chi-square test; and survival, which was calculated with the log-rank test.
‡ In cohort 1, 34 patients underwent transcatheter arterial chemoembolization, 3 received chemotherapy, 1 received in-
terferon alfa therapy, and 1 received lymphokine-activated killer-cell therapy; in cohort 2, 72 patients underwent inter-
feron alfa therapy.
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data were based on the expression of approxi-
mately 21,000 mRNA genes (GEO accession num-
ber, GSE5975).23 Multidimensional scaling analy-
sis on the basis of the first three principal 
components of all genes revealed that a majority 
of patients with low miR-26 expression clustered 
separately from those with high miR-26 expres-
sion (Fig. 2A), according to the dichotomized 
expression status of the three miR-26 genes (Fig. 
2A in the Supplementary Appendix). Class-com-
parison analysis showed that the expression of a 
significant number of genes differed between tu-
mors with low miR-26 expression and those with 
high miR-26 expression; the two groups of tu-
mors had 915 significant genes in common (Fig. 
2B in the Supplementary Appendix). SLC2A6 and 
S100P were selected among the differentially ex-
pressed genes for validation by means of qRT-
PCR (Fig. 3 in the Supplementary Appendix). 
Furthermore, multivariate analysis showed that 
mRNA signatures could significantly predict the 
stratification of patients according to miR-26 ex-
pression, with 80.3% overall accuracy. Thus, pa-
tients whose tumors had low miR-26 expression 
had genetic-expression patterns that were distinct 
from those of tumors in patients with high miR-
26 expression.
Among the 915 overlapping genes, 770 were 
overexpressed in patients with low miR-26 ex-
pression. Gene-network analyses with the use of 
these 770 genes revealed a series of putative tu-
morigenesis networks that had a high score 
(>10) (for details, see Table 4 in the Supplemen-
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Figure 1. Expression of miR-26 in Hepatic Tumors  
and Noncancerous Tissue in Men and Women. 
Panel A shows miR-26a-1 expression in noncancerous 
hepatic tissue from 30 women and 194 men, as deter-
mined by microarray analysis with the use of an unpaired 
t-test. Panel B shows miR-26a expression in noncancer-
ous hepatic tissue obtained from 26 women and 56 age-
matched men, as determined by quantitative reverse-
transcriptase–polymerase-chain-reaction assay with 
the use of an unpaired t-test. In Panels A and B, the 
horizontal lines in the box plots represent the median, 
the boxes represent the interquartile range, and the 
whiskers represent the 2.5th and 97.5th percentiles. 
Panel C shows comparisons of relative levels of miR-
26a-1 expression in paired tumor and nontumor samples 
from 224 patients, according to miR-26 status, with the 
use of paired t-tests. The data in Panels A through C 
are log2 relative expression levels, normalized to the 
values in disease-free samples from eight control sub-
jects. Panel D shows survival according to the level of 
miR-26a-1 expression in tumor samples, as determined 
by microarray analysis, with the use of the log-rank test. 
The median expression level was used as the cutoff. 
Reduced miR-26 expression in 106 patients was classi-
fied as values below the 50th percentile (with a mean 
reduction in tumor tissue, as compared with nontumor 
tissue, by a factor of 2.69). High miR-26 expression in 
111 patients was classified as values at or above the 
50th percentile (with a mean reduction in tumor tissue, 
as compared with nontumor tissue, by a factor of 0.98).
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF HONG KONG LIBRARIES on December 29, 2010. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 361;15 nejm.org october 8, 20091442
33p9
1.0
0.0
0.5
−0.5
−1.0
−1.0
−1.5
−0.5
0.0
0.5
1.0
1.5
−1.5
−1.5
−1.0
−0.5
0.0
0.5
1.0
1.5
B Activation of Gene Networks              
A Patterns of mRNA Expression, According to miR-26 Status
AUTHOR:
FIGURE:
JOB:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Ji
2 of 3
10-08-09
ARTIST: ts
36115 ISSUE:
High miR-26
Low miR-26
TMED10
FKBP14
SPCS3
APBB2
REG1A
CIB2
SBNO2
RP9
TUBA1B
CAMK1
RAB27B
NFATC2
LDHA
S100P
TNFRSF14
ERC1
TRAF1
TRAF2
RIPK3
NUP62
NOL14
SLC2A6
TRIB3
CDH22
LY96
CCL8
SAP30
RBCK1
GRB7
BCR
GMFB
C5AR1
HNMT
SLC4A2
PNPT1
DIABLO
RAB33B
IL6
NF-κB
NF-κB
GORASP2
XBP1
HNF1A
BRE
BCL3
MTPN
Iκb
IKK
IL17A
IL1
5-HT
PRL
PIM1
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF HONG KONG LIBRARIES on December 29, 2010. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
microRNA, Survival, and Interferon Response in Liver Cancer
n engl j med 361;15 nejm.org october 8, 2009 1443
tary Appendix). Examination of the enriched 
genes in various categories revealed several im-
portant signaling networks, the most striking of 
which showed predominant activation of the 
signaling pathway between nuclear factor κB 
(NF-κB) and interleukin-6 in patients with low 
miR-26 expression (Fig. 2B). To validate which 
genes were associated with this signaling path-
way, we measured the level of the NF-κB target 
gene, IL6, by qRT-PCR, since it was also related 
to hepatocellular carcinoma and the disparity in 
miR-26 expression levels between the sexes. Most 
of the patients with hepatocellular carcinoma 
who had reduced miR-26 expression had a con-
comitant elevation in interleukin-6 expression 
(Fig. 4 in the Supplementary Appendix). With 
these findings taken together, we concluded that 
tumors with low miR-26 expression had a dis-
tinct genetic profile.
Validation with Independent Cohorts
To validate the association between the sex-depen-
dent expression of miR-26 and survival, we de-
tected mature miR-26 expression by qRT-PCR in 
tumor and nontumor tissues obtained from pa-
tients in cohort 2. Since adjuvant therapy with 
interferon alfa altered the survival outcome, we 
analyzed the control group. Consistent with co-
hort 1, miR-26 expression was more abundant in 
nontumor tissues obtained from women, but a 
significant reduction was observed in tumors, 
regardless of sex (Fig. 5 in the Supplementary 
Appendix). Moreover, reduced miR-26 expression 
in tumors was significantly associated with 
shorter survival (Fig. 3A, and Fig. 6A in the Sup-
plementary Appendix). The results were similar 
in another independent cohort (cohort 3) (Fig. 3B, 
and Fig. 6B in the Supplementary Appendix).
We used Cox proportional-hazards regression 
to further evaluate the association between miR-
26 expression and prognosis in control subjects 
in cohort 2 (Table 5 in the Supplementary Appen-
dix). In univariate analysis, the level of miR-26a 
expression in tumors and TNM stage were sig-
nificantly associated with the prognosis. The fi-
nal multivariate model revealed that reduced miR-
26a expression in tumors was an independent 
predictor of shorter survival. A similar trend was 
found for miR-26b. Thus, the dichotomized val-
ues for miR-26 expression were independent pre-
dictors of prognosis.
Expression of miR-26 and Response  
to Interferon Alfa
In cohort 2, we analyzed associations between 
miR-26 expression and the response to inter-
feron alfa. Patients with reduced miR-26a expres-
sion in tumors had a significant improvement in 
overall survival after receiving adjuvant therapy 
with interferon alfa, as compared with those in 
the control group (P = 0.003) (Fig. 3C). This find-
ing was validated in cohort 3 (Fig. 3D). In con-
trast, patients with high miR-26a expression in 
both cohorts did not have a response to inter-
feron alfa (Fig. 3E and 3F). Similar results were 
obtained with respect to miR-26b expression 
(Fig. 6C through 6F in the Supplementary Ap-
pendix).
We used Cox proportional-hazards regression 
to evaluate the effect of treatment on survival in 
patients in cohort 2 who had low miR-26 expres-
sion (Table 2). In both univariate and multivari-
ate analyses, interferon alfa was associated with 
significant improvement in survival in patients 
with reduced miR-26 expression. A significant 
interaction was observed between miR-26 ex-
pression and interferon alfa therapy with respect 
to the effect on survival (miR-26a, P = 0.004 for 
interaction; miR-26b, P = 0.02 for interaction). 
Thus, miR-26 expression emerged as an indepen-
dent predictor of the response to interferon alfa.
Figure 2 (facing page). Distinct Transcriptional 
 Activities in Hepatocellular Carcinomas with Low  
miR-26 Expression.
Panel A shows a multidimensional scaling plot, based 
on the expression of 11,580 genes, for 224 patients with 
hepatocellular carcinoma. The plots are placed in three-
dimensional space, spanned by the first three principal 
components of these genes. The level of miR-26 expres-
sion was dichotomized on the basis of the median value 
as low (blue) or high (red). Panel B shows the activation 
of gene networks of signaling between nuclear factor 
κB (NF-κB) and interleukin-6 (IL6) in tumors with low 
miR-26 expression. Shaded ovals represent up-regulated 
genes in tumors with low miR-26 expression, and open 
ovals represent genes that are not on the list of signifi-
cant genes but are reported to be associated with the 
network. The open ovals that are labeled as NF-κB, Iκb, 
and IKK represent molecular nodes related to protein 
complexes of NF-κB, inhibitor of NF-κB, and Iκb kinase, 
respectively. The open oval labeled as 5-HT (5-hydroxytryp-
tamine) represents a chemical node related to serotonin 
receptor signaling, as categorized by pathway analysis 
software (Ingenuity). Arrows represent positive regula-
tion of gene expression, with solid arrows indicating di-
rect regulation and broken arrows indirect regulation.
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Figure 3. Association between miR-26a Expression in Tumors and Overall Survival in Two Trials of Interferon Alfa.
Panels A and B show the association between miR-26a expression and overall survival in patients with hepatocellu-
lar carcinoma from two control groups (cohort 2 in Panel A and cohort 3 in Panel B). In cohort 2, 24 patients had 
high miR-26a expression and 35 patients had low miR-26a expression. In cohort 3, 21 patients had high miR-26a ex-
pression and 19 patients had low miR-26a expression. Panels C and D show the association between adjuvant therapy 
with interferon alfa and overall survival in patients with tumors with low miR-26a expression. In cohort 2, there were 
24 patients in the group that received interferon alfa and 35 patients in the control group. In cohort 3, there were 20 
patients in the group that received interferon alfa and 19 patients in the control group. Panels E and F show the as-
sociation between adjuvant therapy with interferon alfa and overall survival in patients with tumors that had high 
miR-26a expression. In cohort 2, there were 35 patients in the group that received interferon alfa and 24 patients in 
the control group. In cohort 3, there were 19 patients in the group that received interferon alfa and 21 patients in the 
control group.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF HONG KONG LIBRARIES on December 29, 2010. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
microRNA, Survival, and Interferon Response in Liver Cancer
n engl j med 361;15 nejm.org october 8, 2009 1445
Discussion
We analyzed microRNA profiles in predominant-
ly HBV-related hepatocellular carcinomas in men 
and women and the association of microRNA 
expression levels with survival and response to 
therapy with interferon alfa in three independent 
cohorts. We found that the expression of miR-
26a and miR-26b in nontumor hepatic tissues 
was higher in women than in men, but the ex-
pression was significantly down-regulated in tu-
mor samples, as compared with paired samples 
of noncancerous tissues, regardless of sex. Tumors 
with reduced miR-26 expression had a distinct 
gene-expression profile, and patients whose tu-
mors had low miR-26 expression had shorter sur-
vival but were more likely to have a response to 
interferon alfa, as compared with patients whose 
tumors had high miR-26 expression.
Our results suggest that miR-26 may be a 
tumor suppressor and that miR-26 silencing in 
hepatocytes may contribute to the development 
of a more aggressive form of hepatocellular car-
cinoma in men. These hypotheses are supported 
by the following findings: miR-26 was expressed 
at higher levels in women than in men in the 
liver, where presumably more anticarcinogenic 
activities exist in women; miR-26 expression is 
silenced in a subgroup of patients who have re-
duced survival; and genes that are activated in 
tumors with reduced miR-26 expression are se-
lectively enriched in signaling pathways between 
NF-κB and interleukin-6. It was recently reported 
that MyD8-dependent interleukin-6 induction by 
NF-κB differed between male and female mice.11 
Intriguingly, estrogens inhibit interleukin-6 pro-
moter activity, which may contribute to a de-
creased susceptibility to hepatocellular carcinoma 
Table 2. Hazard Ratios for Death among Patients with Low Expression of miR-26a and Patients with Low Expression of miR-26b, 
According to Univariate and Multivariate Analyses.*
Variable Reduced miR-26a Expression(N = 59)
Reduced miR-26b Expression
(N = 58)
Hazard Ratio
(95% CI) P Value†
Hazard Ratio
(95% CI) P Value†
Univariate analysis
Interferon alfa vs. control 0.2 (0.1–0.6) 0.003 0.4 (0.2–0.9) 0.04
Age (≤50 yr vs. >50 yr) 1.1 (0.6–2.2) 0.77 0.9 (0.5–1.8) 0.81
Sex (male vs. female) 1.3 (0.4–3.7) 0.65 1.4 (0.4–4.7) 0.57
Alpha-fetoprotein (>20 ng/ml vs. ≤20ng/ml) 1.8 (0.8–4.1) 0.15 1.9 (0.9–4.0) 0.10
Cirrhosis (yes vs. no) 0.7 (0.3–2.1) 0.57 0.7 (0.3–1.8) 0.43
Alanine aminotransferase (>50 U/liter vs.  
≤50 U/liter)
1.1 (0.4–3.0) 0.79 1.9 (0.8–4.6) 0.17
Tumor size (>3 cm vs. ≤3 cm) 1.7 (0.8–3.6) 0.15 2.0 (1.0–4.3) 0.06
Tumor encapsulation (no vs. yes) 1.8 (0.9–3.6) 0.12 1.6 (0.8–3.1) 0.20
Multinodular tumor (yes vs. no) 0.9 (0.3–2.3) 0.82 1.1 (0.4–2.6) 0.87
TNM staging (II or III vs. I) 2.7 (1.3–5.5) 0.005 2.7 (1.4–5.3) 0.004
Multivariate analysis
Interferon alfa vs. control 0.3 (0.1–0.7) 0.005 0.4 (0.2–0.9) 0.04
TNM staging (II or III vs. I) 2.4 (1.2–4.9) 0.02 2.6 (1.3–5.1) 0.007
Sex (male vs. female) 1.4 (0.5–4.0) 0.55 1.5 (0.5–5.1) 0.48
* The analyses were performed with the use of Cox proportional-hazards regression on data from patients with a low level of miR-26 expres-
sion in cohort 2.
† A P value of less than 0.05 was considered to indicate statistical significance. 
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in women. Whether such a link is functionally 
relevant to liver cancer in humans remains to be 
determined.24 Our results are consistent with 
these findings, since interleukin-6 expression 
was inversely correlated with miR-26 expression.
Our analyses revealed that miR-26 expression 
was an independent predictor of survival. How-
ever, when outcomes of therapy with interferon 
alfa were stratified, only patients whose tumors 
had reduced miR-26 expression had a favorable 
response to interferon alfa in two independent, 
prospective, randomized, controlled trials. These 
results indicate that miR-26 status in tumors may 
be a useful tool in estimating prognosis in pa-
tients with hepatocellular carcinoma and in as-
sisting in the selection of patients who are likely 
to benefit from adjuvant therapy with interferon 
alfa to prevent relapse. In an evaluation of the 
effects of adjuvant interferon alfa therapy after 
liver resection or tumor ablation in seven ran-
domized, controlled trials, Clavien5 concluded 
that all the trials showed modest beneficial ef-
fects of the drug. In addition, among multiple 
experimental agents, only a modest survival ben-
efit has been observed with sorafenib.6 The poor 
efficacy of current systemic agents may stem 
from an inability to identify a subpopulation of 
patients who may have a favorable response to 
a particular therapy. Prospective studies will be 
necessary to determine whether interferon alfa 
might be used as a first-line therapy for patients 
with hepatocellular carcinoma who have under-
gone resection and who have tumors with re-
duced miR-26 expression.
It should be noted that our results involved 
Chinese patients with a high rate of HBV positiv-
ity (90.5%). Our findings therefore need to be 
confirmed by studies of tumors from non-Asian 
patients and tumors arising from other underly-
ing liver diseases, such as hepatitis C, or associ-
ated with alcohol abuse.
The mechanisms behind the sensitivity of tu-
mors with reduced miR-26 expression to therapy 
with interferon alfa are unclear. One plausible 
model is that such tumors have specific activa-
tion of the signaling pathway that is responsive 
to interferon alfa. Consistently, tumors with low 
miR-26 expression were distinct from those with 
high miR-26 expression in transcriptomic activi-
ties and were associated with poor survival. Many 
of the genes that are overexpressed in tumors 
with reduced miR-26 expression are related to 
cell immunity, such as those encoding proinflam-
matory and antiinflammatory cytokines (i.e., inter-
leukin-1, interleukin-2, interleukin-10, and inter-
leukin-17). Moreover, many signaling networks 
that are activated in tumors with low miR-26 ex-
pression are immune-associated, such as NF-κB–
interleukin-6, interleukin-10, STAT3, and inter-
feron alfa inducible factor signaling networks 
(Table 4 in the Supplementary Appendix). Tumors 
with low miR-26 expression may be character-
ized by a unique activation of interferon alfa 
signaling, possibly through the NF-κB–inter leu-
kin-6 signaling pathway, and thus may be sensi-
tive to growth inhibition mediated by interferon 
alfa through interleukin-6–STAT3 signaling.25 
These hypotheses require evaluation.
In conclusion, we identified systematic differ-
ences in patterns of microRNA expression be-
tween liver tissues obtained from men and women 
with hepatocellular carcinoma. Tumors with low 
miR-26 expression were biologically distinct from 
those with high expression and were associated 
with reduced survival but had a favorable response 
to adjuvant therapy with interferon alfa.
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